Quantum-Si Introduces World’s First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor
18 Janvier 2024 - 2:30PM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
that it has entered into an agreement with a new distributor who
will make the company’s protein sequencing instrument, Platinum®
available for the first time in Japan.
TOMY Digital Biology Co., Ltd., a renowned importer and
distributor with a rich history dating back to the 1950s, will
distribute Quantum-Si’s next-generation protein sequencer™ and
associated consumables throughout Japan. “Working with Quantum-Si
marks a pivotal moment for TOMY Digital Biology, aligning with our
commitment to advancing life sciences. We’re poised to empower
Japanese researchers with cutting edge technology, fostering
unparalleled discoveries,” said Kenjiro Tominaga, Owner, President
and CEO of TOMY Digital Biology.
TOMY Digital Biology’s commitment to delivering cutting-edge
solutions and its alignment with Quantum-Si's vision for scientific
innovation make this a significant step forward in providing
researchers in Japan access to state-of-the-art technology for
next-generation protein sequencing™.
Jeff Hawkins, CEO of Quantum-Si, expressed his enthusiasm about
this move, stating: "We are thrilled to work with TOMY Digital
Biology to introduce Platinum, our revolutionary protein sequencing
instrument, to the vibrant scientific community in Japan. We
believe that through TOMY's exceptional distribution capabilities
and our groundbreaking technology, we will empower researchers in
Japan to achieve new milestones in their scientific endeavors."
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
www.quantum-si.com
About TOMY Digital Biology Co., Ltd.
TOMY Digital Biology Co., Ltd. spun off from TOMY Seiko, a
manufacturer of scientific research instruments in 2001. TOMY
Digital Biology has two functions, import and export. One
department imports unique life science research products from other
countries and distributes them to the Japan market. The other
department exports TOMY products to other countries. Learn more at
www.digital-biology.co.jp
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the impact of COVID-19 on the
Company's business; the inability to maintain the listing of the
Company's Class A common stock on The Nasdaq Stock Market; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; our ongoing
leadership transition; changes in applicable laws or regulations;
the ability of the Company to raise financing in the future; the
success, cost and timing of the Company's product development and
commercialization activities; the commercialization and adoption of
the Company’s existing products and the success of any product the
Company may offer in the future; the potential attributes and
benefits of the Company’s commercialized Platinum™ protein
sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240118517534/en/
Investor Contact Jeff Keyes, Chief Financial Officer
ir@quantum-si.com Media Contact Katherine Atkinson, SVP of
Commercial Marketing media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Quantum Si (NASDAQ:QSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024